GSK3511294 · Exdensur

What is GSK3511294?

Depemokimab-ulaa (Exdensur) is a humanized IgG1 monoclonal antibody that antagonizes IL-5, blocking its binding to the IL-5 receptor alpha chain on eosinophils. By inhibiting IL-5 signaling, it reduces eosinophil production and survival.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Exdensur

Drug type

Monoclonal antibody

Targets

IL-5

Mechanism

Antagonist of IL-5

Pathways

eosinophil differentiation and survival, eosinophil recruitment and activation

Therapy area

Respiratory

Developer

Glaxosmithkline Llc

In trials of

IQV

FDA status

Approved as Exdensur (December 16, 2025), BLA761458 · FDA label

UNII

D16EQP0KKH

✅ FDA-approved uses

• Severe asthma characterized by an eosinophilic phenotype

From the indications section of the FDA label (version of Jun 10, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Asthma

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Exdensur (2026-06-10), indications
• ClinicalTrials.gov NCT04718389

Updated Oct 3, 2026.